How Recent Data Impacts Pancreatic Cancer Management

Integrity CE

M. Pishvaian

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Pract…

2024 ESMO Annual Meeting Insights Hub

H. Babiker

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

E. Dotan

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

L. Zheng

Updates in Perioperative Therapy of Pancreatic Cancer

Horizon CME

P. Philip

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

W. Burns

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ecancer

J. Knox

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

UCLA Health

Z. Wainberg

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Yale Cancer Center

J. Lacy

ASCO® 2024 Insights: "Efficacy, Safety, and PD of CM24 With Nivo & C…

2024 ASCO® Annual Meeting Insights Hub

T. Macarulla

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

Insights from 2023 ASCO® Annual Meeting

Y. Janjigian, S. Cytryn, S. Maron

Year in Review: Pancreatic Cancers

OncoAlert

M. Lewis

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

Shubham Pant

Selecting Patients Wisely for Neoadjuvant Therapy in Pancreatic and …

ecancer

S. Shrikhande

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

ASCO GI 2023 Conference Coverage

N. Uboha, A. Turk, K. Spencer, M. Cecchini

ASCO GI 2023 Key Studies

ASCO GI 2023 Conference Coverage

R. Kim, R. Mehta

GI Controversies: Neoadjuvant Tx of Pancreatic Cancer and Liquid Bio…

OncoAlert

B. Westphalen

Updates on Pancreatic Cancer - 2023 ASCO® Direct Philadelphia

Total Health

D. Lin

ESMO 2023 Insights: "A Multicenter, Randomized, Open-Label, Three-Ar…

Insights from 2023 ESMO Annual Meeting

A. Ohba

ASCO® 2024 Insights: "GABARNANCE Trial - Gemcitabine + nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

M. Ikeda